Literature DB >> 22679312

Unilateral lymphadenopathy due to the use of granulocyte colony stimulating factor.

Ning Zhang1, Jie Min, Feng Xiao Huang, Fei Lan, Lili Liu, Helong Zhang.   

Abstract

A 36-year-old woman was admitted to our hospital after modified radical mastectomy operation. Adjuvant chemotherapy was administered using TAC regimen. Severe neutropenia occurred after chemotherapy. Granulocyte colony stimulating factor (G-CSF) was given to treat neutropenia. On the second day of G-CSF use, the patient complained of swelling of her neck on the left side, which subsided spontaneously after discontinuation of G-CSF medication. However, the same symptom recurred following G-CSF use on the second cycle of chemotherapy. B-mode ultrasound showed swollen lymph nodes and biopsy revealed no evidence of metastasis. Therefore, the unilateral lymphadenopathy is considered to be the side effect of G-CSF, which is very rare.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22679312      PMCID: PMC3185385          DOI: 10.1136/bcr.05.2011.4210

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

Review 1.  Aggressive recurrence of gastric cancer as a granulocyte-colony-stimulating factor-producing tumor.

Authors:  Masahiko Kawaguchi; Yasuyuki Asada; Takuro Terada; Akira Takehara; Yoshinori Munemoto; Katsunori Fujisawa; Takeshi Mitsui; Yoshiro Iida; Shoji Miura; Yoshiko Sudo
Journal:  Int J Clin Oncol       Date:  2010-02-24       Impact factor: 3.402

Review 2.  EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.

Authors:  M S Aapro; D A Cameron; R Pettengell; J Bohlius; J Crawford; M Ellis; N Kearney; G H Lyman; V C Tjan-Heijnen; J Walewski; D C Weber; C Zielinski
Journal:  Eur J Cancer       Date:  2006-06-05       Impact factor: 9.162

3.  Side effects related to cancer treatment: CASE 2. Splenic rupture following pegfilgrastim.

Authors:  Muhammad Arshad; Karen Seiter; Jaroslaw Bilaniuk; Anila Qureshi; Asawari Patil; Gita Ramaswamy; Delong Liu
Journal:  J Clin Oncol       Date:  2005-11-20       Impact factor: 44.544

4.  Florid histiocytic hemophagocytosis following therapy with long acting G-CSF (pegfilgrastim).

Authors:  Lewis Glasser; Mark Legolvan; Harold M Horwitz
Journal:  Am J Hematol       Date:  2007-08       Impact factor: 10.047

Review 5.  Safety of long-term administration of granulocyte colony-stimulating factor for severe chronic neutropenia.

Authors:  M H Freedman
Journal:  Curr Opin Hematol       Date:  1997-05       Impact factor: 3.284

Review 6.  The use of cytokine-stimulated healthy donors in allogeneic stem cell transplantation.

Authors:  Simone Cesaro; Piero Marson; Maria Vittoria Gazzola; Giustina De Silvestro; Roberta Destro; Marta Pillon; Elisabetta Calore; Chiara Messina; Luigi Zanesco
Journal:  Haematologica       Date:  2002-08       Impact factor: 9.941

Review 7.  Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (g-csf). A case report and review of the literature.

Authors:  Nabil M Nuamah; Hakan Goker; Yusuf A Kilic; Hassen Dagmoura; Atilla Cakmak
Journal:  Haematologica       Date:  2006-05       Impact factor: 9.941

8.  Granulocyte colony-stimulating factor expression as a prognostic biomarker in non-small cell lung cancer.

Authors:  G P Stathopoulos; A Armakolas; T Tranga; H Marinou; J Stathopoulos; H Chandrinou
Journal:  Oncol Rep       Date:  2011-03-22       Impact factor: 3.906

9.  Richter's syndrome showing pronounced lymphadenopathy in response to administration of granulocyte colony-stimulating factor.

Authors:  Y Kawachi; S Ozaki; Y Sakamoto; T Uchida; M Mori; K Setsu; K Tani; S Asano
Journal:  Leuk Lymphoma       Date:  1994-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.